Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing small-molecule product candidates for serious diseases such as oncology and obesity, has seen a significant decline in its share price following the pricing of its upsized public offering. On 10 September 2024, the company announced it would offer 11,919,048 shares of common stock at $10.50 per share. […]
TERN-201 NASH clinical trial : Terns Pharmaceuticals said that an ongoing phase 1 trial of its semicarbazide-sensitive amine oxidase (SSAO) inhibitor TERN-201 in non-alcoholic steatohepatitis (NASH) has yielded positive results. According to the US biopharma company, the early-stage NASH clinical study showed that a single oral dose of TERN-201 delivered a sustained, near-complete suppression of […]
